Scotiabank Lifts Merck Price Target to $180

Scotiabank has raised its price target for Merck to $180 from $155, according to TipRanks.

The change is based on backtested results and assumes certain market conditions. It's worth noting that backtested performance is not an indicator of future actual results and may have under- or over-compensated for the impact of material economic and market factors.

Merck's stock price has been subject to fluctuations, but Scotiabank's revised target suggests a positive outlook on the company's prospects. However, investors should be aware that actual performance may differ significantly from backtested results.